1
|
Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, Bechter E, Blank J, Bordas V, Dammassa E, Decker A, Di Nanni N, Dourdoigne M, Gavioli E, Hattenberger M, Heuser A, Hemmerlin C, Hinrichs J, Kerr G, Laborde L, Jaco I, Núñez EJ, Martus HJ, Quadt C, Reschke M, Romanet V, Schaeffer F, Schoepfer J, Schrapp M, Strang R, Voshol H, Wartmann M, Welly S, Zécri F, Hofmann F, Möbitz H, Cortés-Cros M. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature 2024:10.1038/s41586-024-07350-y. [PMID: 38658754 DOI: 10.1038/s41586-024-07350-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Accepted: 03/26/2024] [Indexed: 04/26/2024]
Abstract
The Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens1-6. Despite advances in treatment with immune checkpoint inhibitors7-10, there is an unmet need in the treatment of MSI cancers11-14. Here we report the structural, biochemical, cellular and pharmacological characterization of the clinical-stage WRN helicase inhibitor HRO761, which was identified through an innovative hit-finding and lead-optimization strategy. HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation. Pharmacological inhibition by HRO761 recapitulated the phenotype observed by WRN genetic suppression, leading to DNA damage and inhibition of tumour cell growth selectively in MSI cells in a p53-independent manner. Moreover, HRO761 led to WRN degradation in MSI cells but not in microsatellite-stable cells. Oral treatment with HRO761 resulted in dose-dependent in vivo DNA damage induction and tumour growth inhibition in MSI cell- and patient-derived xenograft models. These findings represent preclinical pharmacological validation of WRN as a therapeutic target in MSI cancers. A clinical trial with HRO761 (NCT05838768) is ongoing to assess the safety, tolerability and preliminary anti-tumour activity in patients with MSI colorectal cancer and other MSI solid tumours.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Jutta Blank
- Novartis BioMedical Research, Basel, Switzerland
| | | | | | | | | | | | - Elena Gavioli
- Novartis BioMedical Research, Basel, Switzerland
- Novartis Pharma AG, Basel, Switzerland
| | | | - Alisa Heuser
- Novartis BioMedical Research, Basel, Switzerland
| | | | | | - Grainne Kerr
- Novartis BioMedical Research, Basel, Switzerland
| | | | - Isabel Jaco
- Novartis BioMedical Research, Basel, Switzerland
| | - Eloísa Jiménez Núñez
- Novartis BioMedical Research, Basel, Switzerland
- Pierre Fabre Laboratories, Toulouse, France
| | | | | | | | | | | | | | | | - Ross Strang
- Novartis BioMedical Research, Basel, Switzerland
| | - Hans Voshol
- Novartis BioMedical Research, Basel, Switzerland
| | | | - Sarah Welly
- Novartis BioMedical Research, Basel, Switzerland
| | | | - Francesco Hofmann
- Novartis BioMedical Research, Basel, Switzerland
- Pierre Fabre Laboratories, Toulouse, France
| | | | | |
Collapse
|
2
|
Zhang A, Seiss K, Laborde L, Palacio-Ramirez S, Guthy D, Lanter M, Lorber J, Vulpetti A, Arista L, Zoller T, Radimerski T, Thoma C, Hebach C, Tschantz WR, Karpov A, Hollingworth GJ, D'Alessio JA, Ferretti S, Burger MT. Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates. Bioconjug Chem 2024; 35:140-146. [PMID: 38265691 DOI: 10.1021/acs.bioconjchem.3c00535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Abstract
Antibody-drug conjugates (ADCs) are an established modality that allow for targeted delivery of a potent molecule, or payload, to a desired site of action. ADCs, wherein the payload is a targeted protein degrader, are an emerging area in the field. Herein we describe our efforts of delivering a Bruton's tyrosine kinase (BTK) bifunctional degrader 1 via a CD79b mAb (monoclonal antibody) where the degrader is linked at the ligase binding portion of the payload via a cleavable linker to the mAb. The resulting CD79b ADCs, 3 and 4, exhibit in vitro degradation and cytotoxicity comparable with that of 1, and ADC 3 can achieve more sustained in vivo degradation than intravenously administered 1 with markedly reduced systemic exposure of the payload.
Collapse
Affiliation(s)
- Alan Zhang
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Katherine Seiss
- Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Laurent Laborde
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Sebastian Palacio-Ramirez
- Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Daniel Guthy
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Mylene Lanter
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Julien Lorber
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Anna Vulpetti
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Luca Arista
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Thomas Zoller
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | | | - Claudio Thoma
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Christina Hebach
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - William R Tschantz
- Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Alexei Karpov
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | | | - Joseph A D'Alessio
- Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | | | - Matthew T Burger
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| |
Collapse
|
3
|
Gómez-García-Toraño I, Laborde L, Fichot F, Mutelle H. Reflooding of degraded cores in ASTEC V2.1: Modelling and validation on PEARL experiments. Nuclear Engineering and Design 2022. [DOI: 10.1016/j.nucengdes.2022.111768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Gómez-García-Toraño I, Laborde L. Modelling reflooding of intact core geometries in ASTEC V2.1: Improvements and validation on PERICLES experiments. Nuclear Engineering and Design 2021. [DOI: 10.1016/j.nucengdes.2021.111157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Belaroussi Y, Cousin S, Carton M, Lebitasy M, Laborde L, Laurent C, Filleron T, Fajole G, Dejean V, Parent D, Loeb A, Habet T, Chambon A, Desroys du Roure V, Faralli H, Lebouc M, Pallenchier S, Simon G, Martin A, Mathoulin-Pélissier S. Real-world outcomes for patients with metastatic non-small cell lung cancer according to first-line treatment. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2021.04.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Tsige-Tamirat H, Perez-Martin S, Pfrang W, Anderhuber M, Gerschenfeld A, Laborde L, Mikityuk K, Peniguel C, Mimouni S. A Review of Models for the Sodium Boiling Phenomena in Sodium-Cooled Fast Reactor Subassemblies. Journal of Nuclear Engineering and Radiation Science 2021. [DOI: 10.1115/1.4051066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Abstract
The Euratom Horizon-2020 project ESFR-SMART aims to enhance the safety and performance of the European Sodium-cooled Fast Reactor (ESFR) considering safety objectives envisaged for Generation-IV reactors and the update of European and international safety frameworks, taking into account the Fukushima accident. Further, the project aims to support the development and validation of the computational tools for the situations to be considered in each defense-in-depth level in order to support the safety assessments using data produced in the project as well as selected legacy data. Within this activity, the focus is on the assessment and when needed further development of computer codes for the analysis of the sodium thermal-hydraulics phenomena in SFR subassemblies under operational and accidental conditions including sodium boiling and transitional convection from forced to natural/mixed convection. In support of this activity, a review is performed for the sodium boiling models used in the codes participating in benchmark activities within the project. The objective of the present paper is to summarize the result of the review, which encompasses both the phenomenological and mathematical models implemented in the codes. In particular, the review addresses the physical bases of sodium boiling models, the analytical models in connection with the numerical implementations in the codes and the geometry representations ranging from one-dimensional single channel and finite volume to full three-dimensional CFD and porous media representations. Finally the needs for further developments are discussed.
Collapse
Affiliation(s)
| | - Sara Perez-Martin
- Karlsruhe Institute of Technology, Institute of Neutron Physics and Reactor Technology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - Werner Pfrang
- Karlsruhe Institute of Technology, Institute of Neutron Physics and Reactor Technology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - Marine Anderhuber
- Atomic and Alternative Energies Commission, Nuclear Energy Division, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - Antoine Gerschenfeld
- Atomic and Alternative Energies Commission, Nuclear Energy Division, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - Laurent Laborde
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), 13115 Saint Paul Lez Durance Cedex, France
| | | | | | | |
Collapse
|
7
|
Perez-Martin S, Anderhuber M, Laborde L, Girault N, Lombardo C, Ammirabile L, Mikityuk K, Mimouni S, Peniguel C, Pfrang W. Evaluation of sodium boiling models using KNS-37 LOF experiments. Journal of Nuclear Engineering and Radiation Science 2021. [DOI: 10.1115/1.4050769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Abstract
The computational codes used in the evaluation of the ESFR-SMART reactor performance and specifically their sodium boiling models are assessed using two KNS-37 LOF experiments, i.e. L22 and L29 tests, where boiling onset and two-phase flow regime up to dry-out occurred. The well-equipped KNS-37 experimental facility provided very valuable information for understanding the physical phenomena occurring in a 37-pin subassembly under LOF conditions, as well as experimental data to be used for computational tools validation. NATOF-2D, SAS-SFR, TRACE, ASTEC-Na, CATHARE-2 & CATHARE-3 and NEPTUNE_CFD codes have been used in this exercise in order to compare the various boiling models and conclude on the advantages and limitations of them based on the comparison against the experimental data. Beyond boiling onset, the various sodium two-phase flow approaches determine the ability of the code to correctly represent the rewetting and voiding phases as well as cladding dry-out onset. A simulation performed by a CFD approach (NEPTUNE_CFD code) considering liquid-vapor interfaces by an interface-tracking method is also shown and compared with the others approaches. Conclusions on each code performance are presented where the improvements needed to solve the issues encountered are included. This paper provides a first step in the process to investigate the required evaluation of the sodium two-phase flow models able to assess the safety of new SFR core designs (e.g. low void cores) under accidental conditions such as ULOF transients.
Collapse
Affiliation(s)
- Sara Perez-Martin
- Karlsruhe Institute of Technology, Institute of Neutron Physics and Reactor Technology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - Marine Anderhuber
- Atomic and Alternative Energies Commission, Nuclear Energy Division, CEA Saclay, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - Laurent Laborde
- Institut de Radioprotection et de Sûreté Nucléaire, Nuclear Safety Division, Department of Major Accidents, CEA Cadarache, 13115 Saint Paul Lez Durance Cedex, France
| | - N. Girault
- Institut de Radioprotection et de Sûreté Nucléaire, Nuclear Safety Division, Department of Major Accidents, CEA Cadarache, 13115 Saint Paul Lez Durance Cedex, France
| | - Calogera Lombardo
- Italian National Agency for New Technologies Energy and Sustainable Economic Development, FSN-SICNUC-SIN Safety of Nuclear Installations, Via Martiri di Monte Sole 4 40100 Bologna, Italy
| | - Luca Ammirabile
- European Commission / Joint Research Centre Petten, Westerduinweg 3. 1755LE Petten
| | - Konstantin Mikityuk
- Paul Scherrer Institut, Nuclear Energy and Safety Division, 5232 Villigen, Switzerland
| | - Stéphane Mimouni
- Electricite de France, R&D EDF Lab Chatou, 6 Quai Watier, 78400 Chatou, France
| | - Christophe Peniguel
- Electricite de France, R&D EDF Lab Chatou, 6 Quai Watier, 78400 Chatou, France
| | - Werner Pfrang
- Karlsruhe Institute of Technology, Institute of Neutron Physics and Reactor Technology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| |
Collapse
|
8
|
Gómez-García-Toraño I, Laborde L. Validation of Selected Cesar Friction Models of the ASTECV21 Code Based on Moby Dick Experiments. Journal of Nuclear Engineering and Radiation Science 2019. [DOI: 10.1115/1.4042119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In the event of a loss of integrity of the main coolant line, a large mass and energy release from the primary circuit to the containment is to be expected. The temporal evolution of such depressurization is mainly governed by the critical flow, whose correct prediction requires, in first place, a correct description of the different friction terms. Within this work, selected friction models of the CESAR module of the Accident Source Term Evaluation Code (ASTEC) V2.1 integral code are validated against data from the Moby Dick test facility. Simulations are launched using two different numerical schemes: on the one hand, the classical five equation (drift flux) approach, with one momentum conservation equation for an average fluid plus one algebraic equation on the drift between the gas and the liquid; on the other hand, the recently implemented six equation approach, where two differential equations are used to obtain the phase velocities. The main findings are listed hereafter: The use of five equations provides an adequate description of the pressure loss as long as the mass fluxes remain below 1.24 kg/cm2 s and the gas mass fractions below 5.93 × 10 − 4. Beyond those conditions, the hypotheses of the drift flux model are exceeded and the use of an additional momentum equation is required. The use of an additional momentum equation leads to a better agreement with the experimental data for a wider range of mass fluxes and gas mass fractions. However, the qualitative prediction for high gas mass fractions still shows some deviations due to the decrease of the regular friction term at the end of the test section.
Collapse
Affiliation(s)
- I. Gómez-García-Toraño
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Cadarache, bât 702, Saint-Paul-lez-Durance 13115, France e-mail:
| | - L. Laborde
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Cadarache, bât 702, Saint-Paul-lez-Durance 13115, France e-mail:
| |
Collapse
|
9
|
Perez-Martin S, Pfrang W, Girault N, Cloarec L, Laborde L, Buck M, Matuzas V, Flores y Flores A, Raison P, Smith A, Mozzani N, Feria F, Herranz L, Farges B. Development and assessment of ASTEC-Na fuel pin thermo-mechanical models performed in the European JASMIN project. ANN NUCL ENERGY 2018. [DOI: 10.1016/j.anucene.2017.12.061] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Bandini G, Ederli S, Perez-Martin S, Haselbauer M, Pfrang W, Herranz L, Berna C, Matuzas V, Flores y Flores A, Girault N, Laborde L. ASTEC-Na code: Thermal-hydraulic model validation and benchmarking with other codes. ANN NUCL ENERGY 2018. [DOI: 10.1016/j.anucene.2017.12.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Jacquet E, Lardy-Cleaud A, Pistilli B, Cottu P, Delaloge S, Debled M, Vanlemmens L, Anne-Valérie G, Leheurteur M, Laborde L, Jacot W, Berchery D, Coudert B, Ferrero JM, Parent D, Diéras V, Velten M, Courtinard C, Robain M, Bachelot T. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Laborde L, Oz F, Ristov M, Guthy D, Sterker D, McSheehy P. Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer. Cancer Chemother Pharmacol 2017; 80:869-878. [PMID: 28779265 DOI: 10.1007/s00280-017-3407-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Accepted: 07/25/2017] [Indexed: 12/19/2022]
Abstract
PURPOSE Everolimus is a drug used successfully in a number of different oncology indications, but significant on-target toxicities exist. We explored the possibility of improving the therapeutic index (TI) by studying alternative means of administering the drug based upon low continuous dosing. METHODS All studies were performed using naïve nude mice or nude mice bearing s.c. human renal 786-O tumours or human breast MDA-MB-468 tumours. Everolimus was administered via a standard emulsion, either i.v., p.o., i.p., s.c., or via s.c. osmotic mini-pumps (MP) or via poly-lactic-co-glycolic (PLGA)-microparticles (PLGA-µP) prepared from everolimus powder injected s.c. Total-drug levels in blood, plasma or tissues were quantified ex vivo by LC-MS/MS. Efficacy studies were performed over 2-3 weeks and toxicity assessed by changes in body weight, glucose and white blood cell count. Effects on tumour activity biomarkers were quantified using reverse-phase protein array. RESULTS Everolimus administration s.c. in an emulsion decreased the absorption rate but increased the C max and bio-availability of everolimus compared to standard approaches of administration p.o. or i.p. Everolimus administration s.c. via MP or PLGA-µP reduced the C max and provided continuous low concentrations of everolimus in the plasma, which inhibited tumour pS6/S6 to a similar degree to oral administration. Toxicities such as changes in body weight or white blood cell count were unaffected. Provided the everolimus concentration was above the free unbound IC50 for proliferation of the tumour cell line, efficacy could be achieved equivalent to that provided by standard oral administration. However, an overall improvement in the TI could not be demonstrated. CONCLUSIONS Continuous low plasma concentrations of everolimus can provide strong efficacy in preclinical models, which if translatable to the clinic may reduce on-target toxicities and so increase the TI.
Collapse
Affiliation(s)
- Laurent Laborde
- Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Fatos Oz
- Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Mitko Ristov
- Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Daniel Guthy
- Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Dario Sterker
- Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Paul McSheehy
- Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland. .,Basilea Pharmaceutica International AG, Grenzacherstrasse 487, Postfach 4005, Basel, Switzerland.
| |
Collapse
|
13
|
Guesmia T, Courtinard C, Bachelot F, Mons M, Jaffre A, Guizrad A, Bleuse J, Arveux P, E. Chamorey, Breton M, Laborde L, Parent D, Perol D, Robain M. Données de vraie vie en oncologie. Méthodologie de constitution d’une plateforme de données exhaustives multisources : l’exemple de la base ESME. Rev Epidemiol Sante Publique 2017. [DOI: 10.1016/j.respe.2017.03.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
14
|
Gómez-García-Toraño I, Sánchez-Espinoza VH, Stieglitz R, Stuckert J, Laborde L, Belon S. Validation of ASTECV2.1 based on the QUENCH-08 experiment. Nuclear Engineering and Design 2017. [DOI: 10.1016/j.nucengdes.2016.12.039] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Rahal S, Boher JM, Extra JM, Tarpin C, Charafe-Jauffret E, Lambaudie E, Sabatier R, Thomassin-Piana J, Tallet A, Resbeut M, Houvenaeghel G, Laborde L, Bertucci F, Viens P, Gonçalves A. Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. BMC Cancer 2015; 15:697. [PMID: 26466893 PMCID: PMC4607139 DOI: 10.1186/s12885-015-1746-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 10/09/2015] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Anthracycline-based adjuvant chemotherapy improves survival in patients with high-risk node-negative breast cancer (BC). In this setting, prognostic factors predicting for treatment failure might help selecting among the different available cytotoxic combinations. METHODS Between 1998 and 2008, 757 consecutive patients with node-negative BC treated in our institution with adjuvant FEC (5FU, epirubicin, cyclophosphamide) chemotherapy were identified. Data collection included demographic, clinico-pathological characteristics and treatment information. Molecular subtypes were derived from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status and Scarff-Bloom-Richardson (SBR) grade. Disease-free survival (DFS), distant disease-free survival (DDFS) and overall survival (OS) were estimated using the Kaplan-Meier Method, and prognostic factors were examined by multivariate Cox analysis. RESULTS After a median follow-up of 70 months, the 5-year DFS, DDFS and OS were 90.6 % (95 % confidence interval (CI): 88.2-93.1), 92.8 % (95 % CI: 90.7-95) and 95.1 % (95 % CI, 93.3-96.9), respectively. In the multivariate analysis including classical clinico-pathological parameters, only grade 3 maintained a significant and independent adverse prognostic impact. In an alternative multivariate model where ER, PR and grade were replaced by molecular subtypes, only luminal B/HER2-negative and triple-negative subtypes were associated with reduced DFS and DDFS. CONCLUSIONS Node-negative BC patients receiving adjuvant FEC regimen have a favorable outcome. Luminal B/HER2-negative and triple-negative subtypes identify patients with a higher risk of treatment failure, which might warrant more aggressive systemic treatment.
Collapse
Affiliation(s)
- S Rahal
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France.
| | - J M Boher
- Department of Biostatistics, Institut Paoli-Calmettes, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
| | - J M Extra
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
| | - C Tarpin
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France.
| | - E Charafe-Jauffret
- Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
- Aix-Marseille University, Marseille, France.
| | - E Lambaudie
- Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
| | - R Sabatier
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
- Aix-Marseille University, Marseille, France.
| | - J Thomassin-Piana
- Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
| | - A Tallet
- Department of Radiation Oncology, Institut Paoli-Calmettes, Marseille, France.
| | - M Resbeut
- Department of Radiation Oncology, Institut Paoli-Calmettes, Marseille, France.
| | - G Houvenaeghel
- Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
- Aix-Marseille University, Marseille, France.
| | - L Laborde
- Data Management and Analysis Center, Institut Paoli-Calmettes, Marseille, France.
| | - F Bertucci
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
- Aix-Marseille University, Marseille, France.
| | - P Viens
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
- Aix-Marseille University, Marseille, France.
| | - A Gonçalves
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France.
- Aix-Marseille University, Marseille, France.
| |
Collapse
|
16
|
Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, Bergling S, Wilson C, Brümmendorf T, Fritsch C, Garcia-Echeverria C, Sellers WR, Hofmann F, Maira SM. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther 2012; 11:1747-57. [PMID: 22653967 DOI: 10.1158/1535-7163.mct-11-1021] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The pan-phosphoinositide 3-kinase (PI3K) inhibitor BKM120 was found, at high concentrations, to cause cell death in various cellular systems, irrespective of their level of PI3K addiction. Transcriptional and biochemical profiling studies were used to identify the origin of these unexpected and apparently PI3K-independent effects. At 5- to 10-fold, the concentration needed to half-maximally inhibit PI3K signaling. BKM120 treatment caused changes in expression of mitotic genes and the induction of a robust G(2)-M arrest. Tubulin polymerization assays and nuclear magnetic resonance-binding studies revealed that BKM120 inhibited microtubule dynamics upon direct binding to tubulin. To assess the contribution of this off-target activity vis-à-vis the antitumor activity of BKM120 in PI3K-dependent tumors, we used a mechanistic PI3K-α-dependent model. We observed that, in vivo, daily treatment of mice with doses of BKM120 up to 40 mg/kg led to tumor regressions with no increase in the mitotic index. Thus, strong antitumor activity can be achieved in PI3K-dependent models at exposures that are below those necessary to engage the off-target activity. In comparison, the clinical data indicate that it is unlikely that BKM120 will achieve exposures sufficient to significantly engage the off-target activity at tolerated doses and schedules. However, in preclinical settings, the consequences of the off-target activity start to manifest themselves at concentrations above 1 μmol/L in vitro and doses above 50 mg/kg in efficacy studies using subcutaneous tumor-bearing mice. Hence, careful concentration and dose range selection is required to ensure that any observation can be correctly attributed to BKM120 inhibition of PI3K.
Collapse
Affiliation(s)
- Saskia M Brachmann
- NIBR Oncology Disease Area, Novartis Pharma AG, Basel CH4002, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Labarère J, Gelbert-Baudino N, Laborde L, Baudino F, Durand M, Schelstraete C, François P. Determinants of 6-month maternal satisfaction with breastfeeding experience in a multicenter prospective cohort study. J Hum Lact 2012; 28:203-10. [PMID: 22344778 DOI: 10.1177/0890334411429114] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Although a personally defined experience, successful breastfeeding is usually measured with regard to duration. This study investigated the determinants of maternal satisfaction with breastfeeding experience for 907 mothers enrolled in a prospective cohort study. Despite a median breastfeeding duration (18 weeks) that fell short of recommendations, 822 mothers (90.6%) rated their breastfeeding experience as very or fairly satisfactory. Anticipated breastfeeding duration was a determinant of satisfaction only for women who actually breastfeed < 2 months; in this subgroup of mothers, satisfaction rates ranged from 84.6% for those who anticipated breastfeeding < 2 months to 69.8% for those who anticipated breastfeeding > 4 months (P = .01). Smoking during pregnancy and experiencing breastfeeding difficulties after discharge were independently associated with decreased satisfaction. Eliciting the mother's expectations regarding breastfeeding duration may help the lactation consultant in providing appropriate guidance. Future studies should assess maternal satisfaction using validated instruments.
Collapse
Affiliation(s)
- José Labarère
- Quality of Care Unit, Grenoble University Hospital, Grenoble, France.
| | | | | | | | | | | | | |
Collapse
|
18
|
Pavese P, Sellier E, Laborde L, Gennai S, Stahl JP, François P. Requesting physicians' experiences regarding infectious disease consultations. BMC Infect Dis 2011; 11:62. [PMID: 21401916 PMCID: PMC3061908 DOI: 10.1186/1471-2334-11-62] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2010] [Accepted: 03/14/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Solicited consultations constitute a substantial workload for infectious disease (ID) specialists in the hospital setting. The objectives of this survey were to describe requesting physicians' experiences regarding ID consultations. METHODS A cross-sectional survey was conducted in a university-affiliated hospital in France in 2009. All physicians were eligible (n = 530) and received a self-administered questionnaire. The main outcomes were reasons for request and opinion. Secondary outcomes were frequency of request and declared adherence to recommendations. RESULTS The participation rate was 44.7% (237/530). Among the responders, 187 (79%) had solicited the ID consultation service within the previous year. Ninety-three percent of the responders (173/187) were satisfied with the ID consultation. The main reasons for requesting consultations were the need for therapeutic advice (93%), quality of care improvement (73%) and the rapidity of access (61%). ID consultations were requested several times a month by 52% (72/138) of senior physicians and by 73% (36/49) of residents (p = 0.01). Self-reported adherence to diagnostic and therapeutic recommendations was 83% and 79%, respectively. CONCLUSION The respondent requesting physicians expressed great satisfaction regarding ID consultations that they requested principally to improve patient care and to assist in medical decision making.
Collapse
Affiliation(s)
- Patricia Pavese
- Infectious Diseases Unit, Grenoble University Hospital, F-38043, Grenoble, France
| | | | | | | | | | | |
Collapse
|
19
|
Lucau-Danila A, Laborde L, Legrand S, Huot L, Hot D, Lemoine Y, Hilbert JL, Hawkins S, Quillet MC, Hendriks T, Blervacq AS. Identification of novel genes potentially involved in somatic embryogenesis in chicory (Cichorium intybus L.). BMC Plant Biol 2010; 10:122. [PMID: 20565992 PMCID: PMC3017773 DOI: 10.1186/1471-2229-10-122] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2009] [Accepted: 06/22/2010] [Indexed: 05/08/2023]
Abstract
BACKGROUND In our laboratory we use cultured chicory (Cichorium intybus) explants as a model to investigate cell reactivation and somatic embryogenesis and have produced 2 chicory genotypes (K59, C15) sharing a similar genetic background. K59 is a responsive genotype (embryogenic) capable of undergoing complete cell reactivation i.e. cell de- and re-differentiation leading to somatic embryogenesis (SE), whereas C15 is a non-responsive genotype (non-embryogenic) and is unable to undergo SE. Previous studies 1 showed that the use of the beta-D-glucosyl Yariv reagent (beta-GlcY) that specifically binds arabinogalactan-proteins (AGPs) blocked somatic embryo production in chicory root explants. This observation indicates that beta-GlcY is a useful tool for investigating somatic embryogenesis (SE) in chicory. In addition, a putative AGP (DT212818) encoding gene was previously found to be significantly up-regulated in the embryogenic K59 chicory genotype as compared to the non-embryogenic C15 genotype suggesting that this AGP could be involved in chicory re-differentiation 2. In order to improve our understanding of the molecular and cellular regulation underlying SE in chicory, we undertook a detailed cytological study of cell reactivation events in K59 and C15 genotypes, and used microarray profiling to compare gene expression in these 2 genotypes. In addition we also used beta-GlcY to block SE in order to identify genes potentially involved in this process. RESULTS Microscopy confirmed that only the K59, but not the C15 genotype underwent complete cell reactivation leading to SE formation. beta-GlcY-treatment of explants blocked in vitro SE induction, but not cell reactivation, and induced cell wall modifications. Microarray analyses revealed that 78 genes were differentially expressed between induced K59 and C15 genotypes. The expression profiles of 19 genes were modified by beta-GlcY-treatment. Eight genes were both differentially expressed between K59 and C15 genotypes during SE induction and transcriptionally affected by beta-GlcY-treatment: AGP (DT212818), 26 S proteasome AAA ATPase subunit 6 (RPT6), remorin (REM), metallothionein-1 (MT1), two non-specific lipid transfer proteins genes (SDI-9 and DEA1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase), and snakin 2 (SN2). These results suggest that the 8 genes, including the previously-identified AGP gene (DT212818), could be involved in cell fate determination events leading to SE commitment in chicory. CONCLUSION The use of two different chicory genotypes differing in their responsiveness to SE induction, together with beta-GlcY-treatment represented an efficient tool to discriminate cell reactivation from the SE morphogenetic pathway. Such an approach, together with microarray analyses, permitted us to identify several putative key genes related to the SE morphogenetic pathway in chicory.
Collapse
Affiliation(s)
- Anca Lucau-Danila
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
| | - Laurent Laborde
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
- Novartis Pharma AC, ONC/DD 11/BIO Lab MAIRA, Basel, Switzerland
| | - Sylvain Legrand
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
- EA 3061, Biotechnologies Végétales appliquées aux Plantes Aromatiques et Médicinales, Université Jean Monnet, 23 rue du docteur Paul Michelon, F-42000, Saint-Etienne, France
| | - Ludovic Huot
- U1019, UMR8204, Transcriptomics and applied Genomics, Institut Pasteur de Lille, Center for Infection and Immunity of Lille (CIIL), 1 rue du professeur Calmette, F-59019 Lille, France
| | - David Hot
- U1019, UMR8204, Transcriptomics and applied Genomics, Institut Pasteur de Lille, Center for Infection and Immunity of Lille (CIIL), 1 rue du professeur Calmette, F-59019 Lille, France
| | - Yves Lemoine
- U1019, UMR8204, Transcriptomics and applied Genomics, Institut Pasteur de Lille, Center for Infection and Immunity of Lille (CIIL), 1 rue du professeur Calmette, F-59019 Lille, France
| | - Jean-Louis Hilbert
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
| | - Simon Hawkins
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
| | - Marie-Christine Quillet
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
| | - Theo Hendriks
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
| | - Anne-Sophie Blervacq
- UMR USTL-INRA 1281, Stress Abiotiques et Différenciation des Végétaux cultivés, Université Lille1, Cité Scientifique SN2, F-59650 Villeneuve d'Ascq, France
| |
Collapse
|
20
|
Labarère J, Gelbert-Baudino N, Laborde L, Arragain D, Schelstraete C, François P. CD-ROM-based program for breastfeeding mothers. Matern Child Nutr 2010; 7:263-72. [PMID: 21689269 DOI: 10.1111/j.1740-8709.2009.00235.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The vast majority of breastfeeding mothers in Western countries have routine access to multimedia and Internet resources at home. The aim of this study was to assess the effectiveness of a CD-ROM-based intervention in increasing the rates of breastfeeding. We conducted a pre- and post-intervention study involving four control and four intervention maternity units in France. All breastfeeding mothers in intervention units were given a CD-ROM-based program addressing various breastfeeding topics. The primary outcome was any breastfeeding at 4 weeks assessed by follow-up telephone interview. The secondary outcomes included breastfeeding duration, breastfeeding difficulties after discharge and satisfaction with the breastfeeding experience. The rates of any breastfeeding at 4 weeks varied from 88.6% (209/236) to 87.9% (211/240) and from 86.0% (222/258) to 88.0% (228/259) for mothers enrolled in intervention and control maternity units, respectively (P for interaction=0.54). The hazard of breastfeeding discontinuation for mothers enrolled in intervention units did not vary significantly across study periods after adjusting for education level, epidural anaesthesia, breastfeeding assessment score and return to work (P for interaction=0.18). The rates of breastfeeding at 4 weeks remained unchanged when restricting the analysis to the mothers who actually received (87.8% [173/197]) or used [88.2% (105/119)] the CD-ROM during the post-intervention period. No significant differences were found in secondary outcomes between the two study groups. A CD-ROM-based intervention for breastfeeding mothers provides no additional benefit to usual post-natal care. Further study is needed to assess the effectiveness of multimedia packages as part of more intensive multifaceted interventions.
Collapse
Affiliation(s)
- José Labarère
- Quality of Care Unit, Grenoble University Hospital, pavillon Taillefer, 38043 Grenoble Cedex 9, France.
| | | | | | | | | | | |
Collapse
|
21
|
Sustersic M, Meneau A, Drémont R, Paris A, Laborde L, Bosson JL. [Developing patient information sheets in general practice. Proposal for a methodology]. Rev Prat 2008; 58:17-24. [PMID: 19253787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND Health information is patients' wish and right. For general practitioners, it is a duty, a legal obligation and a pre-requisite in any preventive approach. Written information must complete oral information since it improves health care quality. However, in general practice, there are no patient documents which are scientifically valid, understandable and efficient in terms of communication. OBJECTIVE To develop a method for creating patient information sheets and to experiment its feasibility through the development of 125 sheets focused on the most common clinical conditions in general practice. METHOD Research and literature review pour the development of specifications, and creation of 125 sheets following these specifications. RESULTS The specifications developed consist of the 10 following steps: selection of the topic and the objectives, literature review, selection of the sections, drafting, validation of the scientific contents, assessment among patients, validation of the layout, selection of the media, delivery to patients and update. Following these specifications, we developed 125 information sheets. Each of these was reviewed by several physicians and assessed with R. Flesh readability test (the established acceptable threshold value was 40). The 30 sheets associated with the lowest scores were selected and reviewed to improve their overall readability. CONCLUSION Even though some difficulties cannot be avoided when developing patient information sheets, each physician or physician association can create its own documents following the proposed specifications and thus deliver a customized message.
Collapse
|
22
|
Barana O, Basiuk V, Ducobu L, Laborde L, Mazon D, Moreau P, Saint-Laurent F. Integration of advanced feedback control techniques on Tore Supra. Fusion Engineering and Design 2007. [DOI: 10.1016/j.fusengdes.2007.05.054] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Laborde L, Fulcheri J, Gelbert-Baudino N, Schelstraete C, Mathieu M, Durand M, Baudino F, Vié Le Sage F, Gothie I, Roche F, Devoldere C, Salinier C, Gout JP, Plasse M, Caron FM, François P, Labarere J. Intérêt du Breastfeeding Assessment Score pour la prédiction du sevrage précoce de l'allaitement maternel en France. Arch Pediatr 2007; 14:978-84. [PMID: 17512178 DOI: 10.1016/j.arcped.2007.03.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2006] [Revised: 02/09/2007] [Accepted: 03/19/2007] [Indexed: 10/23/2022]
Abstract
BACKGROUND The Breastfeeding Assessment Score (BAS) was derived to help identify mothers at increased risk of early weaning in United States. Data are currently lacking on the accuracy of the BAS for French mother-infant pairs. OBJECTIVE To assess the accuracy of the BAS in a French validation cohort. METHODS We used the original data from a prospective cohort study of 488 mothers who were breastfeeding at discharge in 9 maternity wards in 2005. The outcome measures were assessed using structured follow-up telephone interviews at 4 and 26 weeks. RESULTS The weaning rate was 3% at 14 days of infant age. The corresponding area under ROC curve was 0.73 [0.60-0.85] and was comparable to that observed in the derivation cohort (0.75). For a cut point of 8 recommended by the authors of the BAS, 43% of mother-infant pairs were categorized at high risk and the weaning rate in this subgroup was 5%. The mother-infant pairs with a score lower than 8 had a shorter median breastfeeding duration (18 versus 20 weeks, P=0.02), were more likely to report breastfeeding difficulties after discharge (63% versus 53%, P=0.03), and were less likely to be "very satisfied" with breastfeeding experience (66% versus 77%, P=0.007). CONCLUSION The intrinsic properties of the BAS are robust. However, its use would be of limited interest in France because of the relatively low rate of early weaning. Randomized trials are needed before recommending routine use of BAS-based breastfeeding support intervention.
Collapse
Affiliation(s)
- L Laborde
- Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
AIM To estimate the percentage of breastfeeding mothers with home access to e-technologies and to compare breastfeeding outcomes for mothers with and without access to e-technologies. METHODS We conducted a prospective observational study of 550 breastfeeding mothers discharged from nine maternity units in France. RESULTS Overall, 435 mothers (79%; 95% confidence interval [95% CI], 75-82) had home access to e-technologies. Mothers with access to e-technologies were less likely to be unemployed (6% vs. 15%, p = 0.004), to smoke during pregnancy (8% vs. 16%, p = 0.03), to have a breastfeeding assessment score <8 (39% vs. 59%, p < 0.001) and to use a pacifier (23% vs. 41%, p < 0.001). Although mothers with access to e-technologies had a longer median breastfeeding duration than those without home access to e-technologies (19 vs. 16 weeks, p = 0.02), adjusted hazard ratios for breastfeeding discontinuation (0.85; 95% CI, 0.60-1.21), overall satisfaction rates (73% vs. 67%, p = 0.19) and breastfeeding difficulties after discharge (58% vs. 61%, p = 0.60) were not different for the two groups. CONCLUSION A vast majority of breastfeeding mothers have home access to e-technologies in France. However, access to e-technologies was not independently associated with better breastfeeding outcomes in this study.
Collapse
|
25
|
Vinh Moreau Gaudry V, Laborde L, Mallaret M, Romanet J, Chiquet C. 359 Pratiques hospitalières de prévention dans 23 cas d’endophtalmie post-chirurgie de la cataracte. J Fr Ophtalmol 2007. [DOI: 10.1016/s0181-5512(07)80171-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Mantica P, Van Eester D, Garbet X, Imbeaux F, Laborde L, Mantsinen M, Marinoni A, Mazon D, Moreau D, Hawkes N, Joffrin E, Kiptily V, Pinches S, Salmi A, Sharapov S, Thyagaraja A, Voitsekhovitch I, de Vries P, Zastrow KD. Probing internal transport barriers with heat pulses in JET. Phys Rev Lett 2006; 96:095002. [PMID: 16606270 DOI: 10.1103/physrevlett.96.095002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2005] [Indexed: 05/08/2023]
Abstract
The first electron temperature modulation experiments in plasmas characterized by strong and long-lasting electron and ion internal transport barriers (ITB) have been performed in JET using ion cyclotron resonance heating in mode conversion scheme. The ITB is shown to be a well localized narrow layer with low heat diffusivity, characterized by subcritical transport and loss of stiffness. In addition, results from cold pulse propagation experiments suggest a second order transition process for ITB formation.
Collapse
Affiliation(s)
- P Mantica
- Istituto di Fisica del Plasma P.Caldirola, Associazione Euratom-ENEA-CNR, Milano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|